Navigation Links
Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Date:11/12/2012

CRANBURY, N.J., Nov. 12, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 10:30 a.m. Eastern Time.  The conference will be held at The Pierre Hotel, New York City.

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... The "Operating Room Management Market ... Application (Perioperative, Preoperative, operating room Scheduling), by Component ... Global Forecast to 2019.” defines and segments the ... forecast of value by product, such as data ... the value and volumes of operating room management ...
(Date:11/15/2014)... 2014 The report “Laboratory ... End-User - Global Forecasts to 2019”, defines ... an analysis and forecast of value by ... Osmosis. Along with this, the value of ... regions are also discussed in the report. ...
(Date:11/15/2014)... 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... for the third quarter ended September 30, 2014. ... September 30, 2014 was $7.0 million, compared to $5.8 ... in net loss is mainly driven by higher research ... progress in both our Phase 3 systemic lupus erythematosus ...
(Date:11/12/2014)... , 12. November 2014 /PRNewswire/ ... RaySafe, ist weltweit führend in der ... biomedizinische Tests und Simulationen und diagnostische ... Nach dem erfolgreichen ... nun branchenweit in Hinsicht auf Produktqualität, ...
Breaking Biology Technology:Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Laboratory Filtration Market worth $2,532.6 Million by 2019 - New Report by MarketsandMarkets 2Laboratory Filtration Market worth $2,532.6 Million by 2019 - New Report by MarketsandMarkets 3Laboratory Filtration Market worth $2,532.6 Million by 2019 - New Report by MarketsandMarkets 4Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update 6Fluke Biomedical/Unfors RaySafe rüstet sich für Wachstum in EMEA-Region 2Fluke Biomedical/Unfors RaySafe rüstet sich für Wachstum in EMEA-Region 3Fluke Biomedical/Unfors RaySafe rüstet sich für Wachstum in EMEA-Region 4Fluke Biomedical/Unfors RaySafe rüstet sich für Wachstum in EMEA-Region 5
... Scholarship Award to Middletown High School SophomoreBRISTOL, R.I., March ... commitment of encouraging young women to pursue careers in ... announced a full-scholarship award for one participant during the ... Mersina Simanski, sophomore at Middletown High School, was presented ...
... with Major Biopharmaceutical CompanyBELGIUM, Wis., March 6 ... to announce that its subsidiary, Modular Process Constructors ... to better reflect its vision, and announces that ... major global biopharmaceutical and consumer health company. The ...
... is available in French . , Montreal ... which includes Dr. Irma Lopez from the Research Institute of ... role in the international collaboration that led to the discovery ... and retinitis pigmentosa (RP), two devastating forms of childhood blindness. ...
Cached Biology Technology:GRRL Tech Participant Offered Full Tuition Four-Year Scholarship to Roger Williams University 2GRRL Tech Participant Offered Full Tuition Four-Year Scholarship to Roger Williams University 3Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision 2Discovery of a new retinal gene involved in childhood blindness 2
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
(Date:11/4/2014)... University of Utah engineers developed the first room-temperature fuel ... electricity without needing to ignite the fuel. These new ... off-grid power and sensors. , A study of the ... Society journal ACS Catalysis . , Fuel cells ... a fuel and an oxygen-rich source such as air. ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Jet-fueled electricity at room temperature 2
... Riverside-led team of biomedical scientists has found that a readily ... skin infections, can be used to treat Fragile X ... and the most common cause of autism. The study,s ... a new clinical trial in Toronto, Canada, that will test ...
... species, filling such an important niche in ocean communities ... finding, however, that sea otters can have even farther-reaching ... behavior of another top predator: the bald eagle. ... heights of 250 feet and function much like trees ...
... of the Union Address on January 23, 2007, President Bush ... "We must increase the supply of alternative fuels, by setting ... renewable and alternative fuels in 2017." This mandate ... 2008 Farm Bill and a $45 subsidy per ton of ...
Cached Biology News:UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 2UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 3Decline in Alaskan sea otters affects bald eagles' diet 2Decline in Alaskan sea otters affects bald eagles' diet 3Mandate for biofuels production requires science-based policy and global perspective 2
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Complement factor B (human)...
... JNK (c-Jun NH2-terminal kinase) signal transduction ... MAP kinase pathways in mammals. JNK ... environmental stress, is associated with the ... is implicated in the immune response, ...
... mid-, near- and far-infrared range FT-IR spectrometers ... in their class. Yet all this comes ... Highest-energy throughput: Having a larger and ... to other conventional FT-IRs provides 300%,larger solid ...
Biology Products: